VFA
CBAY

Virtus Fund Advisers’s Cymabay Therapeutics CBAY Stock Holding History

Virtus Fund Advisers’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$391K Buy
+42,485
New +$363K ﹤0.01% 362

Other funds holding CBAY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Virtus Fund Advisers's CBAY Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Cymabay Therapeutics (CBAY) in Q4 2017: 42,485 shares worth $391K. The stake represents ﹤0.01% of the portfolio and ranks #362 among its holdings.

80 funds tracked by Wall St. Rank hold CBAY as of Q4 2017.

  • Virtus Fund Advisers held 42,485 shares of Cymabay Therapeutics worth $391K as of Q4 2017.
  • Cymabay Therapeutics was a new Virtus Fund Advisers position in Q4 2017.
  • Cymabay Therapeutics made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #362 holding.
  • 80 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.